ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TSX: CTX June 13, 2018 - - PowerPoint PPT Presentation

ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

TSX: CTX June 13, 2018 — Laval, Québec

Certain information contained in these materials and to be discussed during this presentation constitute forward-looking information within the meaning

• f applicable securities laws, including, among others, statements concerning the Company’s objectives and strategies to achieve those objectives,

sales of the Company’s products, the Company’s product candidates and the timeline for their development and commercialization, the Company’s future financial condition and performance, potential acquisition and licensing transactions, as well as other statements with respect to management’s beliefs, plans, estimates, and intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts. Such forward-looking information reflect management’s current beliefs as of the date hereof and are based on information currently available to

• Management. Although the forward-looking information contained in these materials and to be discussed during this presentation is based upon what

management believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements. Forward-looking information is based on the Company’s estimates and assumptions, and is subject to risks and uncertainties, that could cause actual results to differ materially from such forward-looking information, including those described in the Company’s annual information form, management discussion and analysis and other documents filed with Canadian securities regulators, copies of which are available under the Company’s profile at www.sedar.com. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

FORWARD-LOOKING STATEMENTS

2

3

Daniel N. Chicoine

Executive Chairman of the Board

4

Serge Verreault

President and Chief Executive Officer

Jose DaRocha

Chief Financial Officer

Approval of the 2017 audited consolidated financial statements Election of directors Appointment of auditors Approval of advance notice provisions for the election of directors Approval of share incentive plan

AGENDA

5

1 2 3 4 5

6

Fiscal 2017 Annual Report and Financial Statements

1

7

Election of the Board of Directors

2

8

Anthony E. Dobranowski Samira Sakhia David A. Copeland John C. London Thomas Schlader Daniel N. Chicoine

ELECTION OF THE BOARD OF DIRECTORS

9

Appointment

• f auditors

3

10

Approval of advance notice provisions for the election of directors

4

11

5 Approval of share

incentive plan

MANAGEMENT PRESENTATION

13

Serge Verreault

President & CEO Remarks

14

DELIVERING TO ALL STAKEHOLDERS

Building trust

People

Shareholders Customers

MISSION To provide accessible science-based skincare solutions through innovation in order to enhance skin health and the overall wellness

• f our consumers

VISION To be a leader in innovative science-based skincare, providing improved outcomes for all of

• ur clients’ skincare concerns

CRESCITA

is a Canadian commercial dermatology company serving the prescription (Rx) & non-prescription (non-Rx) markets

CRESCITA AT A GLANCE

50,000 sqf manufacturing facility in Montreal offering Contract Manufacturing Services and R&D capabilities is distributed by Taro Pharmaceuticals Inc. in the U.S. and by Galderma in ROW Strong sector-specific management team Strong pipeline of RX product candidates and cosmeceuticals 3 established skincare brands 2 patented technologies and 250+ proprietary formulations

15

SALES & DISTRIBUTION FOOTPRINT

Non-Rx brand portfolio

16

PROPRIETARY TECHNOLOGY PLATFORMS

Topical and Transdermal Drug Delivery

MMPE™

Multiplexed Molecular Penetration Enhancer

Combinations of FDA approved excipients deliver actives into or through the skin

Peel & DuraPeel™

Phase-Changing Topical Cream

Phase-changing cream using self-occlusion to deliver actives into or through the skin

Both technologies can be used for Rx and non-Rx products

17

18

RX PRODUCT

• Topical local anaesthetic that provides safe and effective local dermal

analgesia on intact skin Description

• Exclusive licensing agreement with Taro for U.S. rights signed in 2017
• Pliaglis launched in U.S. in Q1-18
• Galderma has ROW distribution rights. Crescita can reacquire starting in 2021
• Potential for a further US$5.25 million in milestones

Commercial Status

• 7% Tetracaine + 7% Lidocaine
• Pain

API / Indication Used for

• Dermal filler injections
• Pulsed-dye laser therapy
• Laser-assisted tattoo removal
• Non-ablative laser facial resurfacing

The only FDA-approved, phase-changing, self-occluding topical anesthetic cream with the highest concentration of Tetracaine and Lidocaine

• Pliaglis until 2020

Patent Status

• Flexicaine, 2nd generation until 2031

2019 & Beyond 2017 2017 cont’d 2018

DRIVING TRANSFORMATION

Acquired of the Alyria product line Amended Knight loan freeing up $6.0M in cash Completed $1.0M convertible debenture financing Paid down long-term debt

• f $4.2M

19

Out-licensed Pliaglis U.S. rights to Taro Advanced Rx product pipeline and reported positive Phase 2 Results for MiCal 1 Defined and implemented 4-pillar growth strategy

Raised $3.5M through Rights offering Announced U.S. launch

• f Pliaglis

Announced first-time ever positive EBITDA Serge Verreault named CEO Pursue transformational

• perational and business

development activities

CORPORATE STRATEGY & FOCUS

Strategic Acquisitions & In Licensing Agreements International Markets & Out-Licensing Agreements Organic Growth Operational Effectiveness – Innovation & Technology Contract Manufacturing Services (CMO)

20

GEARED FOR GROWTH

Rx Milestone Opportunities

Significant milestones and royalties potential from Pliaglis continue Pliaglis re-launch in U.S. market by Taro Pliaglis launch in Canada FDA Approval of “Not for Home Use” label Restriction removal Milestone – U.S. Regulatory approval of Flexicaine

2018

Received 1st Royalty payment of $1.4M from U.S. sales of Pliaglis

2019

MiCal 1 – Potential

• ut-licensing

upfront payment

Focused on organic growth, strategic LM&A, international market expansion and CMO - ONGOING

21

IMPROVING REVENUE & EBITDA

*Adjusted EBITDA is a non-IFRS measure. This term is defined as earnings (loss) from continuing operations before interest, income taxes (recovery), depreciation and amortization, gain on debt renegotiations, net, equity-settled stock-based compensation (“SBC”), goodwill and intangible assets impairment, accretion on the fair value of inventory, and foreign currency (gains) and losses. 22

23

MARKET CAPITALIZATION

and Share Price

$9.1M

$0.65

Q2-17

$8.8M

$0.62

Q3-17

$7.7M

$0.55

Q4-17

$9.5M

$0.45

Q1-18

$17.2M

$0.82

June 12

Strategic Aspiration to be

a profitable $50M revenue-generating commercial dermatology company in 5 years

OUR STRATEGIC TARGET

2018 2020 2023

24

PROXY VOTE COUNT RESULTS

Elect Directors For % Withheld %

▪ Daniel N. Chicoine

91.0% 9.0%

▪ David A. Copeland

91.2% 8.8%

▪ Anthony E. Dobranowski

91.0% 9.0%

▪ John C. London

91.0% 9.0%

▪ Samira Sakhia

91.2% 8.8%

▪ Thomas Schlader

91.2% 8.8%

26

PROXY VOTE COUNT

Election of Directors

For % Withheld %

▪ Appointment of Ernst & Young as auditors

91.4% 8.6%

27

PROXY VOTE COUNT

Appointment of Auditors

For % Withheld %

▪ Approval of Amendment to By-Law Number 1

91.0% 9.0%

28

PROXY VOTE COUNT

Amendment to By-Law Number 1

For % Withheld %

▪ Approval of share incentive plan

84.4% 15.6%

29

PROXY VOTE COUNT

Approval of Share Incentive Plan

THANK YOU ANY QUESTIONS?